Im coming up that driveway hill, and my familys all there
Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia
Acknowledgements The study was supported by the British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/21/25060) to S.M., and an ERC Advanced Investigator Award (740427, BrainEnergy), Wellcome Trust Senior Investigator Award (099222/Z/12/Z), a Rosetrees Trust grant (M153-F2), and a BHF/UK-DRI Centre for Vascular Dementia Research grant to D.A
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN DIABETES THERAPY
Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
)
